Renato Bassan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1539811/publications.pdf

Version: 2024-02-01

46 papers	3,966 citations	304743 22 h-index	233421 45 g-index
46 all docs	46 docs citations	46 times ranked	5255 citing authors

#	Article	IF	Citations
1	Lymphoblastic Lymphoma: a Concise Review. Current Oncology Reports, 2022, 24, 1-12.	4.0	13
2	Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia. Journal of Molecular Diagnostics, 2022, 24, 893-900.	2.8	7
3	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. Haematologica, 2021, 106, 1559-1568.	3.5	49
4	MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL. Cancers, 2021, 13, 2108.	3.7	5
5	Prognostic impact of <scp>KMT2Aâ€AFF1</scp>â€positivity in 926 <scp>BCRâ€ABL1</scp>â€negative Bâ€lineage acute lymphoblastic leukemia patients treated in <scp>GIMEMA</scp> clinical trials since 1996. American Journal of Hematology, 2021, 96, E334-E338.	4.1	3
6	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. Haematologica, 2021, 106, 2578-2587.	3.5	15
7	National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?. BMC Cancer, 2020, 20, 956.	2.6	1
8	Dasatinibâ€“Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. New England Journal of Medicine, 2020, 383, 1613-1623.	27.0	279
9	Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia. American Journal of Hematology, 2020, 95, 1304-1313.	4.1	1
10	Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18â€“65 years: NILG ALL 10/07. Blood Cancer Journal, 2020, 10, 119.	6.2	29
11	Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations. Genes, 2020, 11, 960.	2.4	2
12	High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). Cancers, 2020, 12, 2242.	3.7	5
13	Capture-Based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes. Cancers, 2020, 12, 1505.	3.7	11
14	Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. Therapeutic Advances in Hematology, 2020, 11, 204062072090353.	2.5	23
15	Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. Blood Advances, 2020, 4, 301-311.	5.2	8
16	Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. Leukemia and Lymphoma, 2019, 60, 3482-3492.	1.3	3
17	Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease. Cancers, 2019, 11, 1417.	3.7	7
18	Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. Journal of Hematology and Oncology, 2019, 12, 39.	17.0	81

#	Article	IF	Citations
19	A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica, 2019, 104, 2028-2039.	3.5	68
20	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology, 2019, 24, 337-348.	1.5	48
21	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. Blood Advances, 2019, 3, 1103-1117.	5.2	23
22	New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 3504-3519.	1.6	67
23	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847.	27.0	1,443
24	Selective liver toxicity and therapeutic progress in acute lymphoblastic leukaemia. Lancet Haematology,the, 2017, 4, e346-e347.	4.6	0
25	Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S2-S9.	0.4	20
26	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica, 2016, 101, 1524-1533.	3.5	154
27	Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival. Haematologica, 2016, 101, e245-e248.	3.5	29
28	Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. Biology of Blood and Marrow Transplantation, 2016, 22, 1983-1987.	2.0	77
29	Immunotherapy approaches to treat adult acute lymphoblastic leukemia. Expert Review of Hematology, 2016, 9, 563-577.	2.2	10
30	Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia. Journal of Clinical Oncology, 2016, 34, 300-302.	1.6	9
31	Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 176-176.	1.4	21
32	Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. Haematologica, 2015, 100, 786-793.	3.5	27
33	Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy. Current Hematologic Malignancy Reports, 2015, 10, 86-95.	2.3	22
34	DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014073.	1.3	132
35	Current and future management of Ph/BCR-ABL positive ALL. Expert Review of Anticancer Therapy, 2014, 14, 723-740.	2.4	40
36	Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia â€“ very long followâ€up. British Journal of Haematology, 2014, 167, 724-726.	2.5	4

#	Article	IF	Citations
37	High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica, 2013, 98, 1718-1725.	3.5	40
38	CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. Haematologica, 2012, 97, 568-571.	3.5	25
39	Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. Annals of Hematology, 2012, 91, 73-82.	1.8	36
40	Modern Therapy of Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2011, 29, 532-543.	1.6	425
41	Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood, 2011, 118, 6153-6163.	1.4	227
42	Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica, 2011, 96, 238-244.	3.5	57
43	Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood, 2009, 113, 4153-4162.	1.4	387
44	Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. The Hematology Journal, 2002, 3, 193-200.	1.4	10
45	Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia. Haematologica, 2002, 87, 257-63.	3.5	7
46	Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCRâ€“ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. The Hematology Journal, 2000, 1, 226-234.	1.4	16